Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor in Advanced Cancers
NCT02649790Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2016
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of eltanexor in multiple myeloma (MM), colorectal cancer (CRC), prostate cancer (PCa) and 2 more (10 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Overall Response Rate at 8 years and 5 more. Started Jan 2016; status: completed.
02
Drugs
eltanexor
03
Conditions
multiple myeloma (MM)colorectal cancer (CRC)prostate cancer (PCa)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02649790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649790.